Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.
暂无分享,去创建一个
S. Han | Sun Bean Kim | S. Jeong | N. Ku | J. Choi | Y. Song | So Youn Shin | J. Kim | H. Kim | J. Oh
[1] Anneke Grobler,et al. Integration of antiretroviral therapy with tuberculosis treatment. , 2011, The New England journal of medicine.
[2] Lerato Mohapi,et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.
[3] D. Havlir,et al. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. , 2011, The Journal of infectious diseases.
[4] A. Kiragga,et al. Incident Tuberculosis during Antiretroviral Therapy Contributes to Suboptimal Immune Reconstitution in a Large Urban HIV Clinic in Sub-Saharan Africa , 2010, PloS one.
[5] W. El-Sadr,et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. , 2010, The New England journal of medicine.
[6] C. Peloquin,et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Giulia Marchetti,et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] S. Cole,et al. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence , 2008, AIDS.
[9] F. Altice,et al. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners , 2007, HIV clinical trials.
[10] M. Kozal,et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial , 2006, The Lancet.
[11] Roger Chou,et al. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses , 2006, The Lancet.
[12] S. Karim. Durban 2000 to Toronto 2006: the evolving challenges in implementing AIDS treatment in Africa. , 2006, AIDS.
[13] M. Clerici,et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART , 2006, AIDS.
[14] C. Dye,et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. , 2006, The Lancet. Infectious diseases.
[15] John L. Johnson,et al. Mycobacterium tuberculosis and human immunodeficiency virus type 1 interaction: Pathogenesis and disease modulation in dual infection , 2014 .
[16] R. Weber,et al. Persistent Apoptosis in HIV-1-Infected Individuals Receiving Potent Antiretroviral Therapy Is Associated With Poor Recovery of CD4 T Lymphocytes , 2004, Journal of acquired immune deficiency syndromes.
[17] M. Aliyu,et al. Tuberculosis and HIV disease: Two decades of a dual epidemic , 2003, Wiener Klinische Wochenschrift.
[18] Jeffrey N. Martin,et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.
[19] Caroline A Sabin,et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy , 2003, AIDS.
[20] John L. Johnson,et al. Increased Replication of HIV‐1 at Sites of Mycobacterium tuberculosis Infection: Potential Mechanisms of Viral Activation , 2001, Journal of acquired immune deficiency syndromes.
[21] G. Vanham,et al. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB) , 2000, Clinical and experimental immunology.
[22] Felipe García,et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection , 2000, AIDS.
[23] John L. Johnson,et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda , 2000, AIDS.
[24] C. Sabin,et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.
[25] R. Weber,et al. Highly active antiretroviral therapy during early HIV infection reverses T‐cell activation and maturation abnormalities , 1998 .
[26] Rob J. De Boer,et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.
[27] D. Weissman,et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. , 1996, Journal of immunology.
[28] Dinakar,et al. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. , 1994, The Journal of clinical investigation.
[29] B. Stilwell,et al. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .
[30] R. Weber,et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. , 1998, AIDS.